An Immunohistochemical Analysis to Validate the Rationale behind the Enhanced Immunogenicity of D-Ribosylated Low Density Lipo-Protein

Firoz Akhter1, 2, M. Salman Khan2*, Sarika Singh3, Saheem Ahmad2*

1 Department of Bio-Engineering, Integral University, Lucknow, India, 2 Department of Bio-Sciences, Integral University, Lucknow, India, 3 Department Toxicology, Central Drug Research Institute (CDRI), Lucknow, India

Abstract

Advanced glycation end products (AGEs) are thought to contribute to the abnormal lipoprotein profiles and increased risk of cardiovascular disease in patients with diabetes and renal failure. D-ribose is one of the naturally occurring pentose monosaccharide present in all living cells and is a key component of numerous biomolecules involved in many important metabolic pathways. Formation of D-ribose derived glycated low density lipoprotein (LDL) has been previously demonstrated but no studies have been performed to assess the immune complex deposition in the kidney of rabbits immunized with glycated LDL. In this study, LDL was glycated with D-ribose, and it was further used as an immunogen for immunizing NZW female rabbits. The results showed that female rabbits immunized with D-ribose modified LDL induced antibodies as detected by direct binding and competitive ELISA. The modified LDL was found to be highly immunogenic eliciting high titer immunogen-specific antibodies, while the native forms were moderately immunogenic. The induced antibodies from modified LDL exhibited wide range of heterogeneity in recognizing various proteins and amino acids conformers. Furthermore, our histopathological results illustrated the deposits of immune complex in glomerular basement membrane in rabbits immunized with D-ribose-LDL.

Introduction

Non-enzymatic glycation of proteins is a post-translational modification process [1], leading to the formation of fructosamine [2] and advanced glycation end products (AGEs) [3, 4]. It has also been reported that there is the generation of oxygen free radicals in the formation of early and advanced glycation end-products [5]. Basically, glycation is a condensation of free carbonyl group with a free amino group of DNA, proteins and LDL macromolecules. The reaction proceeds by nucleophilic addition reaction followed by dehydration, cyclization and rearrangement to form AGEs. The role of glucose in the glycation of proteins has been widely studied however the role of other reducing monosaccharides such as D-ribose in glycation and their resulting effects on animal model has received much less attention. AGEs are heterogeneous class of compounds containing a mixture of cyclic and open chain structures out of which large numbers of AGEs are not determined till date. However, few AGEs which are known like pentosidine, carboxymethyl-lysine (CML), carboxyethyl-lysine (CEL), fructosyl-lysine (FL), which plays an important role in atherosclerosis and nephropathy. The lipoprotein glycation process occurs both on the apoprotein B (apoB) and on phospholipid components of LDL. It leads both functional alterations in LDL clearance and increased susceptibility to oxidative modifications [6]. In addition, oxidative stress and other conditions causing oxidation of LDL stimulate the synthesis of nuclear polymers of adenosine diphosphate ribose (ADP-ribose), which in turn can release monomeric ADP-ribose. The bioavailability of D-ribose makes this carbonyl species quite reactive and damaging, therefore having direct implication in diabetes.

There are ample evidences which indicate the role of lipoprotein glycation in the inflammatory reactions in the vessel wall [7]. Various oxidative stresses of different proteins may be involved in proinflammatory immune mechanisms. These may involve innate immune signals, Toll-like receptors [8] and adaptive immunity signals which are both cell-mediated [9] and antibody-mediated [10]. There are ample of evidences supporting the pathogenic role of humoral response to modified lipoproteins [11–14]. This is mainly due to the fact that modified LDL and its corresponding antibodies form modified LDL immune complexes (mLDL-IC), which are able to activate phagocytic cells through engagement of Fc receptors [14]. Engagement of Fc receptors by mLDL-IC is particularly significant because it delivers stronger activating signals to phagocytic cells than the engagement of scavenger receptors by modified LDL [11]. Native LDL was found to be moderately immunogenic in experimental animals, while, modified form of LDL was found to be highly immunogenic [15]. This study was aimed to see the immunogenicity of native and glycated LDL. The cross reactivity experiments were performed to check the specificity of the raised antibodies using various glycated
Materials and Methods

Ethics statement
The immunization work was approved by Institutional Animal Ethical Committee of Integral University, Lucknow, India by approval No: IU/Biotech/Project/CPCSEA/12/20. The animals were treated with utmost care and treatments were done with minimum pain. The in vivo experiments on rabbits were performed according to the ARRIVE guidelines. After the end of experiment the rabbits were sacrificed by the over dosage of thiopental sodium anesthesia by intra venous mode of injection (≥150 mg/kg).

Materials
D-ribose, Tris-HCl, EDTA, PTA, TBA, Protein A-Agarose column were obtained from Sigma, St. Louis, MO. Polystyrene plates obtained from Nunc (Roskilde, Denmark), HSA, Hb, IgG, Poly-L-lysine, Poly-L-arginine, Poly-L-histidine were obtained from MP Biomedicals and LDL, Anti rabbit IgG, pNPP were purchased from Calbiochem. All other chemicals used in this study were of highest analytical grade available in the country.

Glycation of LDL
LDL was modified by using different concentrations of D-ribose [16]. LDL (62.5 µg/ml) was thoroughly mixed with 80 mM of ribose sugar in 100 mM phosphate buffer saline (PBS), pH 7.4 and incubated at 37°C for three weeks, followed by extensive dialysis against phosphate buffer saline to remove unbound constituents. LDL alone was served as control [17]. Various proteins like HSA, Hb, IgG and Poly amino acids like Poly-L-lysine, Poly-L-arginine and Poly-L-histidine were also modified by using D-ribose with same concentration and with the same procedure [17].

Measurement of superoxide anion
To detect the presence of O2$^-•$ anion in the LDL glycation mixture, a cytochrome-c reduction assay was performed. The reaction mixture contained D-ribose (80 mM) and 100 µM cytochrome-c in 20 mM phosphate buffer (pH 7.4). The reduction rate was determined as the increase in absorbance at 550 nm for 10 min at room temperature. Absorbance was taken at one min intervals [18].

Measurement of hydroxyl radical
Detection of hydroxyl radicals was carried out by measuring thiobarbituric acid (TBA) reactive 2-deoxy-D-ribose oxidation products. Reaction mixtures containing 80 mM D-ribose, and LDL (62.5 µg/ml) was incubated at 37°C for two weeks. The degradation of 2-deoxy-D-ribose was measured by adding 1 mL of 2.8% (w/v) trichloroacetic acid, 1 mL of 1% (w/v) thiobarbituric acid followed by heating at 100°C for 10 min. After cooling the absorbance was read at 532 nm [19].

Immunization Schedule
LDL (25 µg), its D-ribose modified counterpart and D-ribose (25 µg) were emulsified with complete Freund’s adjuvant. The complex and 500 µl CFA were injected intramuscularly in the hind leg muscles of rabbits (three animals in each group). Subsequent injections were given in incomplete Freund’s adjuvant until the period of study. Weekly injections of antigen (LDL/D-ribose modified LDL/D-ribose) were given for seven weeks and thus each animal received a total of 175 µg antigen during the course of immunization. One week after the last dose of immunogen, blood was collected and put it at 37°C for 2–3 hours. The serum separated and decomplemented by heating at 56°C for 30 min on the water bath. Preimmune blood was collected prior to immunization. The serum was stored in small aliquots at -80°C with sodium azide (0.1%) as preservative [20].

Estimation of Conjugate diene (CD) and Thiobarbituric acid reducing substance (TBARS) in plasma
The blood from each NZW female rabbit in a given group was collected in heparinized tubes, for 2–3 h, mixed gently by inversion 2–3 times and incubated at 40°C. Plasma was separated from blood by centrifugation at 2,500 rpm for 30 min, aliquoted and stored at −20°C.

For the extraction of lipid contents from plasma, the method of Folch et al. [21] was employed. One volume of plasma was mixed with 5.0 volume of chloroform: methanol (2:1), followed by centrifugation at 1,000 rpm for 5 min to separate the phases. Most of the upper layer was removed; and 3.0 ml of the lower chloroform layer was recovered. The chloroform layer was placed in a test tube and incubated at 45°C till dryness. For the determination of conjugated diene (CD) in plasma, corresponding lipid residues were dissolved in 1.5 ml of cyclohexane and the absorbance was recorded at 234 nm against a cyclohexane blank in a Beckman DU 640 spectrophotometer. The concentration of conjugated diene formation was calculated by using a molar extinction coefficient of 2.52×10$^4$ M$^{-1}$cm$^{-1}$.

Lipid peroxide contents in plasma were assayed by the method of Yagi [22]. Plasma (25 µl) was mixed with 4.0 ml of 0.083 N

Table 1. Effect of CFA, D-ribose, N-LDL and G-LDL on plasma TBARS and Conjugated Diene (CD) in control and treated NZW female rabbits.

| S.No. | Sera                  | Conjugated diene (CD) | TBARS            |
|-------|-----------------------|-----------------------|------------------|
| 1.    | Preimmune sera        | 15.15 nM±0.041 nM     | 0.48 µM±0.044 µM |
| 2.    | CFA immunized sera    | 22.5 nM±0.17 nM       | 0.044 µM±0.006 µM|
| 3.    | D-ribose immunized sera | 27.22 nM±0.73 nM     | 0.09 µM±0.03 µM |
| 4.    | N-LDL immunized sera  | 27.38 nM±0.13 nM      | 0.112 µM±0.042 µM|
| 5.    | G-LDL immunized sera  | 54.76 nM±0.088 nM     | 3.85 µM±0.057 µM |

Each data represents average of three experiments. The values represent the mean ± SD.

doi:10.1371/journal.pone.0113144.t001
H₂SO₄ followed by the addition of 0.5 ml of 10% phosphotungstic acid. The samples were mixed and incubated for 5 min at room temperature and then centrifuged at 3,000 rpm for 10 min. The supernatant was discarded and the sediment was mixed with 2.0 ml of 0.083 N H₂SO₄ and 0.3 ml of 10% phosphotungstic acid. The mixture was centrifuged at 3,000 rpm for 10 min, the sediment was suspended in 4.0 ml of water and 1.0 ml of TBA reagent (a mixture containing equal volumes of 0.67% aqueous TBA solution and glacial acetic acid) was added. The reaction mixture was heated for 60 min at 95°C, cooled and the tubes were centrifuged at 3,000 rpm for 10 min. The absorbance of the supernatant was determined at 532 nm against a reagent blank in an Eppendorf Bio Spectrometer. The concentration of MDA was calculated by using a standard malondialdehyde [23].

Enzyme linked immunosorbent assay (ELISA)

ELISA was performed on polystyrene plates [24] with slight modification. Polystyrene polyborp immunoplates were coated with 100 μl of the D-ribose, native LDL antisera (native LDL antisera) and G-LDL antisera respectively. Each data represents average of three experiments. The values represent the mean ± SD.

Figure 1. Level of induced antibodies against D-ribose-modified LDL. Direct binding ELISA of D-ribose antisera (□), N-LDL antisera (▲), G-LDL antisera (●) and preimmune sera (■). The microtiter wells were coated with D-ribose, N-LDL and G-LDL (10 μg/ml) in direct binding ELISA of D-ribose antisera, native LDL antisera and G-LDL antisera respectively. Each data represents average of three experiments. The values represent the mean ± SD.

doi:10.1371/journal.pone.0113144.g001

Figure 2. Inhibition of serum antibodies against N-LDL and G-LDL binding by D-ribose (●), N-LDL (▲) and G-LDL (■) respectively. The microtiter plate was coated with D-ribose, N-LDL and G-LDL (10 μg/ml) respectively. Each data represents average of three experiments. The values represent the mean ± SD.

doi:10.1371/journal.pone.0113144.g002
Competitive ELISA/Cross reactivity
The antigen-binding specificity of the antibodies was evaluated by competitive ELISA and cross reactivity [25]. In direct binding ELISA D-ribose, N-LDL and G-LDL (0–20 μg/ml) were mixed with constant amount of induced respective sera. In cross reactivity varying amounts of inhibitors like native and D-ribose

Table 2. Cross reaction of anti-D-ribose-modified LDL IgG.

| S.No. | Inhibitors                      | Maximum % inhibition At 20 μg/ml | Concentration for 50% inhibition (μg/ml) | Percent relative affinity |
|-------|--------------------------------|---------------------------------|------------------------------------------|--------------------------|
| 1.    | D-ribose-LDL                   | 82.3±0.71                      | 2.5±0.04                                 | 100±0.04                 |
| 2.    | Native LDL                      | 33.4±0.15                      | --                                       | --                       |
| 3.    | D-ribose-HSA                    | 46.2±1.34                      | --                                       | --                       |
| 4.    | Native HAS                      | 32.1±1.03                      | --                                       | --                       |
| 5.    | D-ribose-Hb                     | 52.03±1.74                     | 18.4±0.12                                | 13.59±0.25               |
| 6.    | Native Hb                       | 24.21±0.78                     | --                                       | --                       |
| 7.    | D-ribose-IgG                    | 48.101±0.86                    | --                                       | --                       |
| 8.    | Native IgG                      | 23.17±0.23                     | --                                       | --                       |
| 9.    | D-ribose-Poly-L-lysine          | 56.8±1.81                      | 15.3±0.22                                | 16.34±0.26               |
| 10.   | Native Poly-L-lysine            | 27.27±0.32                     | --                                       | --                       |
| 11.   | D-ribose-Poly-L-arginine        | 58.312±1.32                    | 13.7±0.11                                | 18.25±0.28               |
| 12.   | Native Poly-L- arginine         | 18.27±0.21                     | --                                       | --                       |
| 13.   | D-ribose-Poly-L-Histidine       | 39.78±0.42                     | --                                       | --                       |
| 14.   | Native Poly-L- Histidine        | 26.022±0.32                    | --                                       | --                       |

Micro titer plates were coated with D-ribose-modified LDL (10.0 μg/mL). Each data represents average of three experiments. The values represent the mean ± SD. doi:10.1371/journal.pone.0113144.t002

Figure 3. Kidney section from female rabbit immunized with native LDL showing normal morphology of glomeruli (a) (Magnification-60x); whereas, Kidney section from female rabbit immunized with D-ribose-modified LDL showing larger glomerular capillary tuft with increased number of nuclei showing proliferation of endothelium and mesengial cells (b & c) (Magnification-60x). Scale bar 100 μm. doi:10.1371/journal.pone.0113144.g003
modified proteins (LDL, HSA, Hb, IgG) and amino acids (Poly-L-lysine, Poly-L-arginine, Poly-L-histidine) (0–20 μg/ml) were mixed with a constant amount of IgG. The mixture was incubated at room temperature for 2 hours and overnight at 4°C. The immune complex thus formed was added to the wells, in place of serum. The remaining steps were same as in direct binding ELISA. Percent inhibition was calculated using the following formula:

Percent Inhibition = \( \frac{A_{\text{inhibited}} - A_{\text{uninhibited}}}{A_{\text{uninhibited}}} \times 100 \).

In order to perform the cross reactivity, firstly the IgG antibodies were isolated using protein-A-Agarose column, based on affinity chromatography.

**Purification of Antibodies**

Immunoglobulin G (IgG) was affinity purified from preimmune and immune sera on a protein A-Agarose column [26]. Serum (0.5 ml) diluted with equal volume of PBS (pH 7.4), was applied to the column (0.9 x 15 cm) pre-equilibrated with above buffer. The wash through was recycled 2–3 times. Unbound IgG was removed by extensive washing with PBS (pH 7.4). The bound IgG was eluted with 0.58% acetic acid in 0.85% sodium chloride [27]. Three milliliter fractions were collected in a measuring cylinder already containing 1 ml of 1 M Tris–HCl, pH 8.5, and absorbance was recorded. The IgG concentration was determined considering 1.4 OD_{280} = 1.0 mg mammalian IgG/ml. The isolated IgG was then dialyzed against PBS (pH 7.4) and stored at −80°C.

**Histopathological study of Kidney Sections**

**Light Microscopic analysis.** Slices of kidney from rabbits immunized with native and modified LDL was fixed in 10% formalin, dehydrated with increasing strength of ethanol, cleared in xylene, and wax impregnated. Paraffin blocks of the kidney pieces were fixed to block holder to cut 5-μm thick sections. Sections were dewaxed with xylene and hydrated using descending grades of alcohol. Hematoxylin (nuclei stain) and cosin (cytoplasmic stain) were used for staining. Again, the sections were dehydrated with ascending grades of alcohol and cleared with xylene before finally mounting in a mixture of distyrene, a plasticizer, and xylene (DPX) for microscopic observation [28].

**Immunofluorescence analysis.** 5 μm thick sections were cut with the help of a cryostat at −30°C. Sections were fixed with acetone on glass slides, incubated with anti-rabbit IgG fluorescein isothiocyanate conjugate (FITC) obtained from Sigma (St. Louis, MO) for 30 min. After three wash with phosphate buffer saline (PBS, pH 7.4), the sections were mounted with 50% glycerol and viewed under fluorescent microscope [28].

**Results**

**Modification of LDL by D-ribose**

We previously demonstrated that in vitro treatment of commercially available LDL with D-ribose results in biophysical and biochemical alterations in LDL to form LDL-AGEs [16].

**Estimation of superoxide anion**

Superoxide generation in the D-ribose modified human LDL was quantitated by a cytochrome c reduction experiment. During incubation of D-ribose with LDL, the formation of superoxide anion was gradually increased in time dependent manner. The incubation of D-ribose with LDL produced 30.5 nmol O2−

*Figure 4. Immunofluorescence of kidney sections of rabbit immunized with native LDL (a); whereas Immunofluorescence of kidney sections of rabbit immunized with D-ribose-modified LDL showing immune complex deposition on GBM (b & c). Scale bar 100 μm. doi:10.1371/journal.pone.0113144.g004*
mL⁻¹ h⁻¹ compared to 2.34 nmol O₂⁻ mL⁻¹ h⁻¹ with D-ribose alone. Superoxide dismutase (SOD) inhibited the superoxide radical generation. Upon, increasing concentration of SOD, the superoxide generation was gradually decreased.

Estimation of hydroxyl radicals

Incubation of 2-deoxy-D-ribose with D-ribose produced 14.2 nmol TBARS mL⁻¹ h⁻¹; however; reaction of LDL with D-ribose in the presence of Fe³⁺ enhanced it to 22.1 nmol TBARS mL⁻¹. Radical scavengers like mannitol, catalase and a metal ion chelator, desferrioxamine significantly inhibited the production of TBARS. TBARS generation was inhibited up to 50.2% when mannitol was used as a scavenger. However, catalase and desferrioxamine inhibited TBARS up to 52.4 and 60.2% respectively. The result suggests that D-ribose-mediated hydroxyl radical generation may be caused by traces of transition metals. Furthermore, it is also being suggested that the redox reactions of iron may facilitate the generation of hydroxyl radical by reaction of LDL and D-Ribose.

Estimation of CD and TBARS in plasma

CD in plasma was significantly increased in D-ribose glycated LDL induced plasma of NZW female rabbit in comparison preimmune plasma while moderately increased in D-ribose, CFA and N-LDL induced plasma (Table 1). TBARS in plasma was also significantly increased in D-ribose glycated LDL induced plasma in comparison to preimmune plasma while a very less or no change in D-ribose, CFA and N-LDL induced plasma (Table 1).

Immunogenicity of LDL and its D-ribose-modified form

In the present study, antigenicity of D-ribose, CFA, native and D-ribose-modified LDL was probed in New Zealand white (NZW) female rabbits. The result from direct binding ELISA D-ribose showed not significant binding, native LDL was moderately immunogenic eliciting average titer of antibodies, while its modified form i.e. glycated LDL was found to be much more immunogenic than its native form (Figure 1). CFA not showed significant binding with its induced sera (data not shown). Native LDL showed the titer value of >1:3200 while D-ribose glycated LDL antisera showed high titer antibodies (>1:25,600) in direct binding ELISA. Binding of the preimmune serum was of low magnitude (Figure 1).

Furthermore, in the competitive inhibition ELISA we used D-ribose glycated LDL antisera to explore its specificity against the immunogen i.e. D-ribose glycated LDL (Figure 2).

The purified IgG from protein A-Agarose column showed single homogenous band on denaturing SDS-PAGE (data not shown).

The IgG antibodies exhibited wide range of heterogeneity in recognizing varied inhibitors that included native and glycated analogues of LDL, HSA, Hb, IgG, poly L-lysine, poly L-arginine and poly L-histidine. A maximum of 82.3% inhibition of the D-ribose-LDL-IgG antibody was observed with the immunogen, when it was used as an inhibitor (Figure 2). The antibody was highly specific for the immunogen as only 2.5 µg/mL D-ribose modified-LDL caused 50% inhibition in the antisera activity (Table 2). The IgG antibody showed considerably low recognition for native LDL, which caused a maximum inhibition of only 33.4%. The inhibition of D-ribose-LDL-IgG antibody by various competitors is given in Table 2. IgG concentration was kept constant (40 µg/ml) in all experiments. The cross reactivity observed with various amino acids (poly L-lysine, poly L-arginine, poly L-histidine) and protein (HSA, Hb, IgG) was due to the recognition of antigenic determinants. Reports show that D-ribose induces maximum modification at arginine and lysine residue in modified LDL case (Table 2), which explains that the higher cross reactivity of antisera with D-ribose-arginine and D-ribose-lysine. This result is corroborated with the previously published reports [29].

In Histopathological study of NZW female rabbit’s immunized with native LDL showing normal morphology of glomeruli (Figure 3a) while female rabbit’s immunized with D-ribose modified LDL showing larger glomerular capillary tuft with increased number of nuclei (Figure 3b and 3c). In the fluorescence microscopic examination, low fluorescence signal was detected in FITC-labelled kidney sections of rabbits immunized with native LDL (Figure 4a) while D-ribose-LDL-immunized rabbit’s kidney section showing GBM having a series of intense fluorescence points (Figure 4b and 4c).

Discussion

The LDL concentration used in these experiments for glycation is 62.5 µg/mL. The average level of LDL in normal individual is 1 mg/ml. However, the level of glycated LDL in diabetic subjects is 30 µg/mL. Therefore, to see the significant change in LDL macromolecule we used double the amount of glycated LDL in diabetic subjects which is 62.5 µg/mL.

Furthermore, a small spectrum of information like body weight, food consumption and illness were observed in phenotypic studies. In-life parameters we have monitored daily clinical observations, weekly body weights. Up to 3rd week of immunization there was no phenotypic changes were observed moreover no significant alterations were found in the total daily food consumption and weekly food consumption without any illness. We also observed that animals immunized with glycated LDL were more prone to reduction in body weight & food consumption as compared to native LDL.

Ribose is a naturally occurring pentose monosaccharide present in all living cells including the blood and is a key component of many important bio-molecules such as riboflavin, RNA and ATP [30]. Our study has shown that D-ribose causes structural perturbations in LDL molecule resulting in the generation of neo-antigenic epitopes which are recognized as non-self by the immune system, thus breaking the immune tolerance existing normally to self-antigens. Previously it has been shown that oxidized form of the LDL is highly immunogenic and shows potential recognition of auto-antibodies raised against modified LDL [31]. This is the first study in which we explored the immunogenicity of native and glycated LDL by D-ribose. Our results also point towards the possible involvement of this pentose sugar in the induction of antibody response in different diseases. Thus, it is reasonable to conclude that at present the exact pathophysiological role of glycation of apo B is still obscure and needs further study.

Vigorous humoral response in animals immunized with D-ribose-modified LDL suggests an alteration in the LDL structure, resulting in the generation of neo-antigenic epitopes which are recognized as non-self by the immune system, leading to the robust production of antibodies.

The half-life of LDL in the circulation is in the order of 3–4 days. Some research groups experimentally showed in rabbits that in vitro glycated low density lipoprotein (glycated-LDL) was cleared at a slower rate than control LDL and thus stayed longer in the circulation (vascular mean residence time: 10 vs 8 h, p less than 0.001). The bodies mean residence time for glycated-LDL was 22 h vs 17 h for control LDL. In diabetic animals the catabolic parameters of both LDL preparations changed towards a faster clearance, the effect being greatest for glycated-LDL (total
mean residence times of glycated-LDL pre-diabetic: 19 h, diabetic: 16 h; control LDL, pre-diabetic and diabetic: 14 h). The difference in clearance between glycated and control LDL was thus strongly reduced. This suggests an increased activity of the non-receptor mediated pathway in diabetes mellitus, possibly was thus strongly reduced. This suggests an increased activity of diabetic: 16 h; control LDL pre-diabetic and diabetic: 14 h).

Histological examination of kidney sections of rabbits immunized with native LDL showed a normal kidney morphology having normal glomerular, tubular, and vascular structure (Figure 3a). Whereas D-ribose-LDL immunized rabbits revealed hyper cellular and congested glomeruli with thickened basement membrane indicative of immune complex deposition (Figure 3b and 3c). In the fluorescence microscopic examination, low fluorescence signal was detected in FITC-labeled kidney sections having a series of intense fluorescence points (Figure 4b and 4c). The deposition of immune complexes in the kidney points toward the possible involvement of D-ribose in glomerulonephritis.

Our research group and others too have shown that D-ribose causes structural perturbations in the LDL molecule [16] resulting in the metabolic abnormalities associated with glycation of LDL molecule that include diminished recognition of LDL by the classic LDL receptor; increased covalent binding of LDL in vessel walls; enhanced uptake of LDL by macrophages, thus stimulating foam cell formation; increased platelet aggregation; generation of neo-antigenic epitopes which are recognized as non-self by the immune system, thus breaking the immune tolerance existing normally to self-antigens. Formation of LDL-immune complexes; and generation of oxygen free radicals, resulting in oxidative damage to both the lipid and protein components of LDL and to any nearby macromolecules. We have also indicated its possible role in glomerulonephritis, an aspect that needs further probe. Our results would pave the way for further studies to evaluate the role of AGE-LDL in the progression and pathophysiology of diabetes-mediated atherosclerosis.

Recently, the presence of auto-antibodies in experimental and diabetes mellitus patients against the glycated DNA was investigated by our group [33–36]. There are also couple of recent reports for the presence of the auto-antibodies in the sera of the cancer patients which needs to be validated further [37]. Therefore the need of the hour is to stop this dreaded reaction using novel approach like nanoconjugation [38,39]. Our research group has recently shown some medicinal plants that have potent antioxidant property like Phyllanthus virgatus, Ficus virens and Boehmeria diffusa [40–42]. Eventually, based on its antioxidant and antidiabetic characteristics, it is hypothesized that these plants might exhibit antiglycating properties as well. This is just a hypothesis to prove the same to get rid of the anomalies happening due to the glycation reaction as discussed above. We hope our findings would also help the way for the treatment of diabetes and its secondary complications like retinopathy, neuropathy and nephropathy.

Acknowledgments

The Authors are highly thankful to the Vice Chancellor of Integral University, Prof. Waseem Akhtar Sb. for the establishment of highly advanced research laboratories in the department of Bio-Sciences and Bio-Engineering.

Author Contributions

Conceived and designed the experiments: FA SA. Performed the experiments: FA SA. Analyzed the data: MSK SA. Contributed reagents/materials/analysis tools: MSK. Contributed to the writing of the manuscript: FA MSK SA.

References

1. Gillery P, Jenison S (2014) Post-translational modification derived products (PTMDPs): toxins in chronic diseases? Clin Chem Lab Med 52(1): 33–38.
2. Lapolla A, Traldi P, Fedele D (2005) Importance of measuring products of non-enzymatic glycation of proteins. Clin Biochem 38: 103–113.
3. Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury. Circulation 114: 597–605.
4. Ahmad S, Shahab U, Baig MH, Khan MS, Khan MS, et al. (2013) Inhibitory effect of metformin and pyridoxine in the formation of early, intermediate and advanced glycation end-products. PLoS One 8(9): e72128.
5. Azevedo M, Falcão J, Raposo J, Manso C (1988) Free Radic Res Commun 4: 331–333.
6. Mironova M, Virella G, Virella-Lowell I, Lopes-Virella MF (1997) Antimodified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopath 85: 73–82.
7. Akanji AO, Abdella N, Mojiminiyi OA (2002) Determinants of glycated LDL levels in non diabetic and diabetic hyperlipidemic patients in Kuwait. Clin Chim Acta 317(1–2): 171–176.
8. Lundberg AM, Hansson GK (2010) Innate immune signals in atherosclerosis. Clin Immunol 134: 5–24.
9. Andersson J, Lobb P, Hansson GK (2010) Adaptive immunity and atherosclerosis. Clin Immunol 134: 33–46.
10. Lopes-Virella MF, Virella G (2010) Clinical significance of the humoral immune response to modified LDL. Clin Immunol 134: 55–65.
11. Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF (2006) OxLDL immune complexes activate complement and induce cytotoxic production by MonoMac 6 cells and human macrophages. J Lipid Res 47: 1975–1983.
12. Lopes-Virella MF, McHenry MB, Lipitz S, Yin E, Wilson PF, et al. (2007) Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 190: 359–369.
13. Yishak AA, Costacou T, Virella G, Zigbor J, Fried L, et al. (2006) Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol Dial Transplant 21: 93–100.
14. Kummoo O, Turunen SP, Wang C, Lehtimäki J, Veneskoski M (2013) Carbamyl adducts on low-density lipoprotein induce IgG response in LDLR−/− mice and bind plasma autoantibodies in humans under enhanced carbamylation. Antioxid Redox Signal 19(10): 1047–1062.
15. Steinberg D (2009) The LDL modification hypothesis of atherogenesis: an update. J Lipid Res 50: S176–S301.
16. Ahmad S, Akhter F, Moinudin, Shahab U, Khan MS (2013) Studies on glycation of human low density lipoprotein: A functional insight into physico-chemical analysis. Int J Biol Macro 62: 167–171.
17. Akhter F, Khan MS, Shahab U, Ahmad S (2013) Bio-physical characterization of ribose induced glycated: A mechanistic study on DNA perturbations. Int J Biol Macromol 50: 206–210.
18. Beauchamp C, Fridovich I (1971) Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal Biochem 44: 276–287.
19. Halliwell B, Gutteridge JMC (1981) Formation of thiobarbituric acid-reactive substance from deoxyhemoglobin in the presence of iron salts: the role of superoxide and hydroxyl radicals. FEBS Lett 128: 347–352.
20. Moinudin, Dixit K, Ahmad S, Shahab U, Habib S, et al. (2012) Human DNA damage by the synergistic action of 4-aminobiphenyl and nitric oxide: An immunochemo-study. Environ Toxicol 29(3): 65–76.
21. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497–509.
22. Yagi K (1987) Lipid peroxides and human diseases. Chem Phys Lipids 45(2–4): 337–51.
23. Liu KT, Lesca P (1982) Pharmacological properties of Dibenzo[a, c]cyclooctene derivatives isolated from Fructus Schizandrae Chinensis III. Inhibitory effects on carbon tetrachloride-induced lipid peroxidation, metabolism and covalent binding of carbon tetra chloride to lipids. Chem Biol Interact 41(1): 39–47.
24. Shahab U, Ahmad S, Moinudin, Dixit K, Habib S, et al. (2012) Hydroxyl Radical Modification of Collagen Type II Increases Its Arthrogenicity and Immunogenicity. PLoS ONE 7(2): e31199.
25. Shahab U, Moinudin, Ahmad S, Dixit K, Habib S, et al. (2013) Genotoxic effect of N-hydroxy-4-acetylamino-phenyl on human DNA: implications in bladder cancer. PLoS One 8(1): e53205.
26. Mustafa I, Ahmad S, Dixit K, Moinudin, Ahmad J, et al. (2012) Glycated human DNA is a preferred antigen for anti-DNA antibodies in diabetic patients. Diabetes Res Clin Pract 93(1): 98–104.
27. Goding JW (1976) Use of staphylococcal protein-A as an immunological reagent. Immuno Methods 20: 241–253.

28. Shahab U, Moinuddin, Ahmad S, Dixit K, Abidi SMA, et al. (2012) Acquired Immunogenicity of Human DNA Damaged by N-Hydroxy-N-acetyl-4-amino-biphenyl. IUBMB Life 64(4): 340–345.

29. Cervantes-Laurean D, Minter DE, Jacobson EL, Jacobson MK (1993) Protein glycation by ADP-ribose: studies of model conjugates. Biochemistry 32(6): 1528–1534.

30. Kellar PJ, Kim SU, Bown DH, Chen HC, Kohule A, et al. (1989) Biosynthesis of riboflavin: mechanism of formation of the ribitylamino linkage. Biochemistry 27: 1117–1120.

31. Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, et al. (2011) Levels of Oxidized LDL and Advanced Glycation End Products Modified LDL in Circulating Immune Complexes Are Strongly Associated With Increased Levels of Carotid Intima-Media Thickness and Its Progression in Type 1 Diabetes. Diabetes 60: 582–589.

32. Kortlandt W, Benschop C, van Rijn HJ, Erkelens DW (1992) Glycated low density lipoprotein catabolism is increased in rabbits with alloxan-induced diabetes mellitus. Diabetologia 35(5): 202–207.

33. Ahmad S, Moinuddin, Shahab U, Habib S, Salman Khan M, et al. (2014) Glycoxidative damage to human DNA: Neo-antigenic epitopes on DNA molecule could be a possible reason for autoimmune response in type 1 diabetes. Glycobiology 24(3): 261–291.

34. Ahmad S, Moinuddin, Habib S, Shahab U, Alam K, et al. (2014) Autoimmune response to AGE-modified human DNA: Implications in type 1 Diabetes mellitus. J Clin. Trans. Endo. 1: 3; 66–72.

35. Ahmad S, Moinuddin, Dixit K, Shahab U, Alam K, et al. (2014) Genotoxicity and immunogenicity of DNA-advanced glycation end products formed by methylglyoxal and lysole in presence of Cu2+. Biochem Biophys Res Commun. 407(3): 568–574.

36. Shahab U, Tabrez S, Khan MS, Akhter F, Khan MS, et al. (2014) Immunogenicity of DNA-advanced glycation end product fashioned through glyoxal and arginine in the presence of Fe3+: its potential role in prompt recognition of diabetes mellitus auto-antibodies. Chemico Biol Int. 219: 229–240.

37. Ahmad MI, Ahmad S, Moinuddin (2011) preferential recognition of methylglyoxal modified calf thymus DNA by circulating autoantibodies in cancer patients. Ind Journal of Biochem and Biophys. 48: 290–296.

38. Rahim M, Iram S, Khan MS, Khan MS, Shukla AR, et al. (2013) Glycation-assisted synthesized gold nanoparticles inhibit growth of bone cancer cells. Colloids Surf B Biointerfaces 117: 473–479.

39. Ahmad S, Khan MS, Khan MS, Akhter F, Khan A, et al. (2014) Glycoxidation of biological macromolecules: A critical approach to halt the menace of glycation. Glycobiology 24: 979–990.

40. Iqbal D, Khan MS, Khan MS, Ahmad S, Srivastava AK (2013) An In Vitro and molecular informatics study to evaluate the antioxidative and β-hydroxy-β-methylglutararyl-CoA reductase inhibitory Property of Ficus virens Ait. Phytother Res doi:10.1002/ptr.5077.

41. Hashim A, Khan MS, Khan MS, Baig MH, Ahmad S (2013) Antioxidant and α-amylase inhibitory property of Phyllanthus virgatus L.: an in vitro and molecular interaction study. Biomed Res Int doi:10.1155/2013/729393.

42. Akhter F, Hashim A, Khana MS, Ahmad S, Iqbal D, et al. (2013) Antioxidant, α-amylase inhibitory and oxidative DNA damage protective property of Boerhaavia diffusa (Linn.) root. S Afr J Biol 68: 265–272.